Lokalise vs Phrase: Make Your TMS FDA Audit Ready with Four Controls
For submission-bound or safety-critical content, an LSP-led, ISO-aligned AI+HUMAN hybrid workflow is the fastest route to an audit-ready translation. A qualified translation management system paired with named, documented specialist review can work for lower-risk, versioned content. For many enterprises, a hybrid model that blends TMS throughput with LSP certification and final QA balances speed and compliance best. The sections below lay out the evidence and the exact controls to demand.
Table of Contents
What “TMS vs specialized LSP” means for regulated content
This comparison is not about software features or user interfaces. It addresses a procurement decision regulated enterprises face constantly: whether to manage regulated translation inside a translation management system, hand it to a specialized language service provider, or combine both.
In scope are document types where translation errors carry regulatory, legal, or patient-safety consequences: instructions for use (IFUs), patient labeling, regulatory submissions, Good Laboratory Practice (GLP) study reports, and SEC filings containing foreign-language source material.
Three U.S. regulatory anchors shape the decision. 21 CFR §801.15 requires that when a device label carries a foreign-language representation, the required label information must also appear in that language. FDA’s Part 11 guidance governs how electronic records and signatures, including those produced inside a TMS, must satisfy predicate-rule requirements. FDA’s GLP translation Q&A sets expectations for signed translation statements accompanying translated study reports. Each anchor turns a vendor choice into a documented compliance decision, not a style preference.
The AI+HUMAN hybrid workflow for audit-ready translation
An audit-ready translation process follows a fixed sequence, and procurement teams can request each step as a line item in an RFP or statement of work.
Asset integration: client translation memories ™ and term bases (TB) are ingested first, so terminology is fixed before generation begins.
LLM generation: a constrained large language model produces target-language output bound by the client’s terminology and style rules, never operating as an open, unsupervised engine.
Certified SME review: a subject-matter expert, qualified in the relevant domain, checks technical accuracy, regulatory consistency, and contextual nuance against the source.
QA aligned to ISO 17100 and ISO 18587: a structured quality check closes the loop, covering completeness, formatting, and terminology compliance.
Each step produces an artifact a reviewer can later audit: TM/TB ingestion logs, generation constraints documentation, reviewer attestations naming the SME and their qualifications, and QA checklists tied to the specific deliverable. For GLP and submission materials, this means a signed and dated translation statement, version-linked source and target files, and an audit log showing who touched the document and when.
Pro Tip: Ask any vendor, TMS-based or LSP, to produce a sample audit trail before you sign, not after your first regulatory inspection.
When to choose an LSP, a TMS, or a hybrid model
Risk level, not document length or word count, should drive the delivery model decision.
LSP-led work is required when: content is submission-bound to FDA, SEC, or another regulator; errors carry safety or legal consequence; the material contains protected health information or personal data; or patient labeling must preserve the exact intent of indications, warnings, and risk-benefit statements from the professional label.
A TMS plus named reviewer can be acceptable when: the content is versioned product documentation or internal release notes, the enterprise has validated the system’s record and audit-trail controls, and a qualified human reviewer is formally assigned and documented.
Validation evidence to confirm either way: audit trails, retention periods, and system qualification records consistent with FDA’s Part 11 guidance, since predicate-rule obligations apply regardless of which software touches the record.
Compliance tooling frameworks built for other regulated functions, such as the decision models described by TrustView for legal professionals, reinforce the same pattern: platform convenience never substitutes for documented accountability.
Applying the criteria: two procurement scenarios
Scenario A, an IFU bound for FDA submission. This falls squarely in LSP-led territory. Mandatory deliverables include a signed and dated translation statement, a named SME attestation covering technical accuracy, a table and figure completeness check against the source document, and QA records aligned to ISO 17100 and ISO 18587.
Scenario B, versioned product documentation managed in a TMS. This can stay inside the TMS if the enterprise can show system qualification evidence and assign a named, qualified reviewer for each release. Acceptable controls include reviewer sign-off logged per version, terminology consistency checks against the term base, and retention of prior versions for comparison.
Classify the document by regulatory destination and safety impact.
Match the classification to the LSP, TMS, or hybrid criteria above.
Demand the specific deliverable list for that scenario before work begins.
Failure modes and how to mitigate them
Three failure patterns account for most audit findings and regulatory objections in translated regulated content.
Meaning drift: translated text shifts tone or technical meaning across revisions. Mitigate with enforced term bases, mandatory SME review, and a post-translation reconciliation pass against the original source.
Version and provenance gaps: a translated document can no longer be tied to a specific source version. Mitigate with document-level linkage, archived source files, a signed translation statement for each deliverable, and a second-person completeness check performed by someone other than the original translator.
System and process gaps: a TMS lacks documented qualification, audit trails, or a retention policy. Mitigate by requiring TMS qualification evidence and SOPs that map system controls directly to predicate-rule obligations before the system handles regulated content.
Pro Tip: Run a reconciliation check on at least one past deliverable from any incumbent vendor before renewing a contract; gaps surface fastest in historical files, not new ones.
Where AD VERBUM fits in this decision
The decision conditions above, submission-bound content, safety-critical labeling, PHI exposure, and the need for ISO-aligned QA with data sovereignty map directly to how we operate. Our AI+HUMAN hybrid workflow runs every regulated project through asset integration, constrained LLM generation, certified SME review, and QA aligned to ISO 17100 and ISO 18587, with no step skipped regardless of deadline pressure.
We draw on a network of subject-matter expert linguists, including medical professionals, engineers, and legal scholars, to staff the SME review step with reviewers qualified in the relevant domain. Our certifications span ISO 9001, ISO 17100, ISO 18587, ISO 13485, ISO 27001, ISO 42001, ISO 14001, and AQAP 2110, independently audited by Bureau Veritas, and our infrastructure aligns to data protection and regulatory compliance frameworks on EU-hosted servers.
A discovery call with our team starts by classifying your content’s risk level, then scopes the evidence package, timeline, and validation steps your specific deliverable requires.
Quick checklist for procurement and compliance
Before signing any translation vendor agreement for regulated content, confirm the following:
Classify every document by regulatory destination and safety impact before quoting delivery models.
Require a signed and dated translation statement for any GLP or submission deliverable.
Require named SME reviewer credentials, not a generic “qualified reviewer” line.
Demand TMS qualification evidence, audit trails, and retention policy documentation if a TMS is part of the workflow.
Ask for a sample audit log and completeness-check report before awarding the contract.
A practitioner’s view on AI adoption in regulated translation
The risk in regulated translation was never the technology choice between a TMS and a human workflow. It is governance: whether every AI-generated draft gets a named, accountable reviewer and whether that review leaves a documented trail. Vendors who lead with speed claims and skip the evidence package are the ones that produce audit findings. Ask for the signed statement, the reviewer’s credentials, and the QA checklist before you ask about turnaround time. If a vendor cannot produce these on request, the workflow is not audit-ready no matter how fast it runs.
— Eric Brown
Get a scoped, compliance-ready translation engagement
We built our process around the exact gaps that cause regulatory findings: missing translation statements, unqualified reviewers, and unlinked versions. A discovery call with our team assesses your content’s risk class, the evidence your regulator expects, your timeline, and whether your existing TMS setup needs added validation controls or a full LSP-led handoff.
What you get from that conversation:
A risk classification for your document set against FDA, GLP, or SEC requirements.
A clear list of deliverables: signed translation statements, SME attestations, and QA records.
A realistic timeline based on our AI+HUMAN hybrid workflow rather than a generic estimate.
Our services page outlines translation, localization, interpretation, and related offerings, or you can start a conversation directly through our contact page.
This article is general information, not a substitute for advice from a qualified lawyer. Consult a qualified legal professional about your own circumstances before acting on anything here.
FAQ
What does “audit-ready” mean for a translated regulatory document?
An audit-ready translation carries a signed and dated translation statement, documented SME reviewer credentials, a completeness check against the source, and a version-linked file trail. These elements let an inspector trace the deliverable back to its source and reviewer without gaps, as outlined in FDA’s GLP translation guidance.
Does FDA require translations to be certified by a specific type of vendor?
FDA guidance does not mandate a single vendor type; it requires that translated GLP study reports be accurate, complete, and accompanied by a signed translation statement, regardless of whether a TMS or an LSP produced the work. The same FDA Q&A requires documented translator qualifications and a completeness check.
Can a TMS alone satisfy FDA Part 11 for translated records?
A TMS can support Part 11 compliance only when the underlying business process, including audit trails, retention, and record validation, has been qualified; the software itself does not satisfy predicate-rule obligations on its own. FDA’s Part 11 guidance stresses that predicate-rule requirements remain enforceable regardless of the platform used.
What certifications should a translation partner hold for regulated work?
Look for ISO 17100 for core translation service requirements and ISO 18587 for post-editing of machine translation output, alongside sector-specific certifications like ISO 13485 for medical devices where relevant. We hold both of these along with ISO 9001, ISO 27001, ISO 42001, and AQAP 2110, independently audited by Bureau Veritas.
How does device label translation interact with FDA requirements?
Under 21 CFR §801.15, when a device label includes a foreign-language representation, all required label information must also appear in that language, making label translation a compliance obligation rather than an optional localization step. Patient labeling translations must additionally preserve the intent of indications and warnings, per FDA’s patient-labeling guidance.
Sources
